Evidence map›Paper›PMID 41827784›Full record

ArticleCancers2026

Germline

Guillaume Meynard, Victor Pereira, Sophie Paget-Bailly, Elodie Klajer, Laura Mansi, Loïc Chaigneau, Nathalie Meneveau, Marie Justine Paillard, Fernando Bazan, Erion Dobi and 10 more

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Guillaume MeynardDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.ORCID 0000-0002-0646-4055
Victor PereiraDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.ORCID 0000-0002-2721-520X
Sophie Paget-BaillyMarie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, F-25000 Besançon, France.ORCID 0000-0003-3327-6452
Elodie KlajerDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.ORCID 0009-0002-5035-7238
Laura MansiDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Loïc ChaigneauDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.ORCID 0000-0002-4938-9470
Nathalie MeneveauDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Marie Justine PaillardDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Fernando BazanDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Erion DobiDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Cristian VillanuevaMontpellier Cancer Centre, Clémentville Clinic, Medical Oncology, 34070 Montpellier, France.
Zohair SelmaniDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Julien ViotDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Lorraine DalensDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Morgan GoujonDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.
Marie-Agnès Collonge-RameDepartment of Oncobiology, Jean Minjoz University Hospital, 25000 Besançon, France.
Céline PopulaireDepartment of Oncobiology, Jean Minjoz University Hospital, 25000 Besançon, France.
Aurélia MeurisseMarie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, F-25000 Besançon, France.
Xavier PivotDepartment of Medical Oncology, ICANS, 67200 Strasbourg, France.ORCID 0000-0003-3689-5013
Elsa CurtitDepartment of Medical Oncology, Jean-Minjoz University Hospital Centre, F-25000 Besançon, France.

Funding

Biomarin Sequencing of the BRCA genes was supported by Biomarin. The funders had no role in study de-sign, data collection and analysis, decision to publish, or preparation of the manuscript.
6 · The paper itself

Abstract

objectivesThis study aimed to fill the data gap regarding the prevalence of germline (g)

methodsA prospective g

resultsAmong 407 included mBC patients, 11 (2.7%) carried pathogenic g

conclusionsThe 2.7% prevalence of g

Indexed as

BRCAbreast cancer susceptibility genegenetic screeningmetastatic breast cancerprevalence

Identifiers

PMID41827784
PMCPMC12984906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.